

HR 6101

Drug Price Transparency in Medicaid Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 1, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 2, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6101>

Sponsor

Name: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Dec 1, 2021
Rep. Carl, Jerry L. [R-AL-1]	R · AL		Jan 11, 2022
Rep. Jacobs, Chris [R-NY-27]	R · NY		Feb 9, 2022
Rep. Meuser, Daniel [R-PA-9]	R · PA		Mar 17, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 2, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 1, 2021)

Drug Price Transparency in Medicaid Act of 2021

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.

Actions Timeline

- **Dec 2, 2021:** Referred to the Subcommittee on Health.
- **Dec 1, 2021:** Introduced in House
- **Dec 1, 2021:** Referred to the House Committee on Energy and Commerce.